Investment to support development of human-compatible xeno organs to address the global organ shortage crisis

11-Nov-2019

eGenesis, a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage, successfully completed a USD 100 million Series B financing. The financing was led by Fresenius Medical Care Ventures ...

more

Agreements signed to divest Currenta and Animal Health

30-Oct-2019

Bayer has made progress in all key areas and is on track both operationally and strategically. “Bayer had a successful third quarter,” Werner Baumann, Chairman of the Board of Management, said on Wednesday during the news conference call on the quarterly figures. “We increased the Group’s sales ...

more

11-Sep-2019

The Supervisory Board of Bayer AG on Tuesday decided to reduce the size of the company’s Board of Management from seven to five members effective January 1, 2020. Dr. Hartmut Klusik (63) and Kemal Malik (56) will leave the company as of December 31, 2019. As part of the previously communicated ...

more

09-Aug-2019

Bayer AG and BlueRock Therapeutics announced an agreement under which Bayer will fully acquire BlueRock Therapeutics, a privately held US-headquartered biotechnology company focused on developing engineered cell therapies in the fields of neurology, cardiology and immunology, using a proprietary ...

more

25-Apr-2019

The Bayer Group achieved a strong start to the year in its operational business. “A major factor in this success was our agriculture business, while Pharmaceuticals also delivered encouraging performance,” said Werner Baumann, Chairman of the Board of Management, on Thursday when presenting the ...

more

01-Mar-2019

Evotec AG announced that another promising small molecule from its multi-target alliance with Bayer has advanced into Phase II clinical development for the treatment of persistent chronic cough. As a result of the trial initiation, Evotec received a payment of € 3 m. In October 2012, Evotec and ...

more

New approach to tumor treatment

01-Nov-2018

Linking therapeutically active molecules to specific antibodies can help to pilot them to their designated targets and minimize side effects—especially when treating tumors. In the journal Angewandte Chemie, scientists have now described novel conjugates made from antibodies and a kinesin spindle ...

more

06-Sep-2018

LEO Pharma and Bayer announced the completion of the relevant closing conditions to allow the transfer of Bayer’s prescription dermatology business to LEO Pharma in the United States. Closing in all other countries is expected during the second half of 2019, subject to the fulfillment of ...

more

Group sales and earnings increase

05-Sep-2018

Bayer successfully completed the biggest acquisition in its history in the second quarter of 2018, while operational performance improved, even without taking into account the newly acquired Monsanto business. Sales advanced at three of the four segments on a currency- and portfolio-adjusted ...

more

15-Aug-2018

Evotec AG announced that Haplogen GmbH, a Vienna-based biotechnology company and collaboration partner of Evotec, has entered into a multi-year drug discovery and development collaboration with Bayer AG to identify new therapeutics with applications in pulmonary diseases such as chronic ...

more